Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1568024

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1568024

Antidiuretic Drugs

PUBLISHED:
PAGES: 178 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Antidiuretic Drugs Market to Reach US$1.1 Billion by 2030

The global market for Antidiuretic Drugs estimated at US$479.4 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 11.9% over the analysis period 2023-2030. Vasopressin Drugs, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$642.7 Million by the end of the analysis period. Growth in the Oxytocin Drugs segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$130.6 Million While China is Forecast to Grow at 16.0% CAGR

The Antidiuretic Drugs market in the U.S. is estimated at US$130.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$227.1 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.

Global Antidiuretic Drugs Market - Key Trends and Drivers Summarized

Why Are Antidiuretic Drugs Becoming Increasingly Vital in Treating Fluid Balance Disorders?

Antidiuretic drugs, also known as vasopressin analogs or antidiuretic hormone (ADH) medications, are a class of pharmaceuticals that help regulate fluid balance in the body by reducing urine production and promoting water reabsorption in the kidneys. These drugs mimic the action of the natural hormone vasopressin, which is produced by the hypothalamus and stored in the pituitary gland, playing a critical role in maintaining homeostasis by controlling water levels in the body. The primary purpose of antidiuretic drugs is to manage conditions where the body cannot adequately retain water, such as in diabetes insipidus, a disorder characterized by excessive urination and thirst due to a lack of or insensitivity to vasopressin. They are also used to treat nocturnal enuresis (bedwetting), certain types of polyuria (increased urine production), and, in some cases, hyponatremia (low blood sodium levels) by regulating water retention. The most commonly used antidiuretic drug is desmopressin, a synthetic analog of vasopressin that selectively acts on the kidneys to increase water reabsorption, thereby reducing urine volume. This targeted action makes antidiuretic drugs invaluable in restoring fluid balance and preventing dehydration, offering significant benefits in managing both acute and chronic conditions related to water metabolism.

How Do Antidiuretic Drugs Impact Various Medical Conditions?

Antidiuretic drugs have a broad therapeutic impact, primarily in managing disorders related to water imbalance, where either excessive loss or retention of fluids poses serious health risks. One of their most prominent uses is in the treatment of diabetes insipidus, where the body is unable to conserve water due to insufficient levels of vasopressin or a reduced response to the hormone. In this condition, antidiuretic drugs such as desmopressin are crucial in significantly reducing the excessive urine output, thereby helping maintain proper hydration and preventing complications like electrolyte imbalances. Additionally, these drugs are employed in managing nocturnal enuresis, particularly in children, by reducing nighttime urine production and improving the child’s ability to hold urine through the night. In the context of polyuria and polydipsia (excessive thirst), conditions often associated with brain injuries, pituitary disorders, or certain genetic syndromes, antidiuretic medications help normalize urine output and alleviate symptoms. Beyond these primary uses, antidiuretic drugs are sometimes used to treat hyponatremia, a condition in which low sodium levels in the blood can lead to severe neurological symptoms. In such cases, careful administration of these drugs can help correct the dilutional effect caused by water retention, stabilizing sodium levels and preventing complications such as seizures and cerebral edema. The versatility of antidiuretic drugs extends to perioperative management as well, where they are used to control excessive bleeding by leveraging vasopressin’s hemostatic properties in surgical settings. As the understanding of fluid balance disorders expands, the clinical applications of these drugs continue to grow, making them an integral part of therapeutic regimens for managing water homeostasis in the body.

What Challenges Do Antidiuretic Drugs Pose in Clinical Practice?

Despite their therapeutic value, antidiuretic drugs present several challenges in clinical practice, particularly concerning their dosing, potential side effects, and patient-specific responses. One of the main issues is the risk of developing hyponatremia, especially in patients with an already compromised electrolyte balance. Hyponatremia can result from overcorrection or inappropriate dosing of antidiuretic drugs, leading to water retention and dangerously low sodium levels in the blood. This risk is heightened in elderly patients and those with cardiovascular or renal conditions, necessitating close monitoring of serum electrolytes during treatment. Another challenge is ensuring adherence, especially in pediatric or geriatric populations, as the management of conditions like nocturnal enuresis or diabetes insipidus often requires long-term use of these medications. The inconvenience of nasal spray administration in children or compliance issues with oral formulations can hinder effective treatment outcomes. Additionally, desmopressin, while effective, has a narrow therapeutic index, meaning that small variations in dose can lead to significant changes in clinical effects, making precise dosing crucial to avoid adverse reactions. There is also the issue of tachyphylaxis, where repeated use of the drug over time leads to a diminished response, requiring higher doses to achieve the same therapeutic effect. Furthermore, certain antidiuretic drugs are contraindicated in patients with a history of thromboembolic events or those at risk of clotting disorders due to their hemostatic effects, complicating their use in these populations. Finally, high costs and limited availability in some regions can pose barriers to accessing these medications, impacting patient care. Addressing these challenges requires a personalized approach to treatment, with careful consideration of the patient’s overall health status, regular monitoring, and adjustments to therapy based on individual responses and risk factors.

What Factors Are Driving the Growth of the Antidiuretic Drug Market?

The growth in the antidiuretic drug market is driven by several factors, primarily the rising prevalence of diabetes insipidus, nocturnal enuresis, and other fluid balance disorders, along with the increasing awareness and diagnosis of these conditions. As healthcare professionals become more adept at recognizing and managing complex endocrine and renal disorders, the demand for targeted therapies like antidiuretic drugs is on the rise. Advances in diagnostic tools and the development of more precise biomarkers have also contributed to earlier and more accurate identification of these conditions, thereby expanding the treatment population. Another critical growth driver is the expanding geriatric population, which is more susceptible to conditions that disrupt water homeostasis, such as heart failure, chronic kidney disease, and age-related hormonal imbalances. The increased incidence of these conditions has spurred demand for effective management solutions like antidiuretic drugs. Moreover, technological advancements in drug formulations, such as the development of longer-acting and more patient-friendly delivery systems (e.g., oral melt tablets and subcutaneous injections), are improving adherence and therapeutic outcomes, thereby boosting market growth. The pharmaceutical industry’s focus on expanding indications for antidiuretic drugs, exploring their use in new therapeutic areas such as postoperative fluid management and in combination therapies for syndrome of inappropriate antidiuretic hormone secretion (SIADH), is further enhancing their market potential. Additionally, growing investments in research and development, particularly in the Asia-Pacific region, where healthcare infrastructure is rapidly advancing, are expected to accelerate the introduction of new and improved drug variants. The availability of generics and biosimilars is also making these treatments more accessible, thereby increasing their adoption globally. As patient awareness and diagnostic capabilities continue to evolve, the antidiuretic drug market is poised for robust growth, driven by the need for safe, effective, and targeted therapies that can improve quality of life for individuals affected by fluid balance disorders.

Select Competitors (Total 37 Featured) -

  • American Remedies Healthcare Private Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Bachem AG
  • Baxter International, Inc.
  • BCN Peptides S.A.
  • Ferring International Center SA
  • Fresenius Kabi USA
  • Hybio Pharmaceutical Co., Ltd.
Show more
Product Code: MCP24063

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Antidiuretic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Diabetes Insipidus Drives Demand for Antidiuretic Medications
    • Increasing Prevalence of Nocturia Expands Market Potential for Antidiuretic Therapies
    • Rising Geriatric Population Propels Demand for Antidiuretic Drugs in Age-Related Disorders
    • Advancements in Drug Formulations Spur Growth in Long-Acting Antidiuretic Products
    • Increasing Focus on Pediatric Care Boosts Adoption of Pediatric-Specific Antidiuretic Medications
    • Growing Awareness of Urinary Disorders Creates Opportunities for Market Growth
    • Innovation in Delivery Mechanisms Propels Adoption of Injectable and Nasal Spray Formats
    • Shift Towards Personalized Medicine Sustains Demand for Targeted Antidiuretic Therapies
    • Rising Adoption in the Treatment of Chronic Kidney Diseases Expands Market Reach
    • Parental Concerns Over Enuresis in Children Drive Demand for Effective Antidiuretic Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antidiuretic Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antidiuretic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Vasopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Vasopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Vasopressin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oxytocin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oxytocin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oxytocin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Desmopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Desmopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Desmopressin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Antidiuretic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Antidiuretic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Antidiuretic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Antidiuretic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!